Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Tarih
2015Yazar
Ramires, Felix J. A.
Calvo, Carlos
Chen, Chen-Huan
Dukat, Andrej
Duarte, Yan Carlos
Erglis, Andrejs
Fu, Michael
Gomez, Efrain
Gonzalez-Medina, Angel
Hagege, Albert A.
Huang, Jun
Katova, Tzvetana
Kiatchoosakun, Songsak
Kim, Kee-Sik
Kozan, Oemer
Llamas, Edmundo Bayram
Martinez, Felipe
Merkely, Bela
Mendoza, Ivan
Mosterd, Arend
Negrusz-Kawecka, Marta
Peuhkurinen, Keijo
Refsgaard, Jens
Rosenthal, Arvo
Senni, Michele
Jr, Antonio S. Sibulo
Silva-Cardoso, Jose
Squire, Iain B.
Starling, Randall C.
Teerlink, John R.
Vanhaecke, Johan
Vinereanu, Dragos
Wong, Raymond Ching-Chiew
Packer, Milton
McMurray, John J. V.
Desai, Akshay S.
Gong, Jianjian
Lefkowitz, Martin P.
Rizkala, Adel R.
Rouleau, Jean L.
Shi, Victor C.
Solomon, Scott D.
Swedberg, Karl
Zile, Michael
Andersen, Karl
Arango, Juan Luis
Arnold, J. Malcolm
Belohlavek, Jan
Boehm, Michael
Boytsov, Sergey
Burgess, Lesley J.
Cabrera, Walter
Üst veri
Tüm öğe kaydını gösterÖzet
Background-Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients.
Koleksiyonlar
- Makale [92796]